MX366124B - Anticuerpos antagonistas del interferón alfa y omega. - Google Patents

Anticuerpos antagonistas del interferón alfa y omega.

Info

Publication number
MX366124B
MX366124B MX2015012728A MX2015012728A MX366124B MX 366124 B MX366124 B MX 366124B MX 2015012728 A MX2015012728 A MX 2015012728A MX 2015012728 A MX2015012728 A MX 2015012728A MX 366124 B MX366124 B MX 366124B
Authority
MX
Mexico
Prior art keywords
antibody antagonists
interferon alpha
interferon
omega
omega antibody
Prior art date
Application number
MX2015012728A
Other languages
English (en)
Other versions
MX2015012728A (es
Inventor
Chichi Huang
Ellen Chi
Jinquan Luo
Galina Obmolova
Ronald Swanson
Judith Connor
Xiefan Lin-Schmidt
Lu Lu
Christian Martinez
Jarrat Jordan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2015012728A publication Critical patent/MX2015012728A/es
Publication of MX366124B publication Critical patent/MX366124B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)

Abstract

La presente invención se refiere a los antagonistas de anticuerpos ampliamente neutralizantes de interferón-a e interferón-w, polinucleótidos que codifican los anticuerpos o fragmentos, y métodos para preparar y usar lo anterior son útiles en el tratamiento de enfermedades asociadas con la producción incrementada de IFNa e IFNw; los IFNs tipo I son una familia de citosinas que todas señalizan mediante un receptor heterodimérico (IFNAR) ubicuamente expresado lo que resulta en efectos antivirales, antiproliferativos e inmunomoduladores.
MX2015012728A 2013-03-15 2014-03-13 Anticuerpos antagonistas del interferón alfa y omega. MX366124B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788302P 2013-03-15 2013-03-15
PCT/US2014/025701 WO2014151422A1 (en) 2013-03-15 2014-03-13 Interferon alpha and omega antibody antagonists

Publications (2)

Publication Number Publication Date
MX2015012728A MX2015012728A (es) 2016-07-06
MX366124B true MX366124B (es) 2019-06-27

Family

ID=51527966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012728A MX366124B (es) 2013-03-15 2014-03-13 Anticuerpos antagonistas del interferón alfa y omega.

Country Status (13)

Country Link
US (3) US9902770B2 (es)
EP (1) EP2970461A4 (es)
JP (2) JP6466904B2 (es)
KR (1) KR20150128849A (es)
CN (1) CN105358575B (es)
AU (2) AU2014235003A1 (es)
CA (1) CA2906526C (es)
EA (1) EA038502B1 (es)
HK (1) HK1220474A1 (es)
IL (1) IL241052B (es)
MX (1) MX366124B (es)
WO (1) WO2014151422A1 (es)
ZA (1) ZA201507659B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
CA2998456A1 (en) 2015-09-15 2017-03-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US10941204B2 (en) * 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
AU2019276776B2 (en) * 2018-06-01 2025-12-11 ILC Therapeutics Limited Compositions and methods relating to the treatment of diseases
WO2020229378A1 (en) * 2019-05-13 2020-11-19 F. Hoffmann-La Roche Ag Interference-suppressed pharmacokinetic immunoassay
GB202003595D0 (en) * 2020-03-12 2020-04-29 Ilc Therapeutics Ltd Compositions and methods relating to the treatment of diseases
WO2025247917A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale ANTI-IFN-α2 AND ANTI-IFN-ω1 MONOCLONAL ANTIBODIES
WO2025247913A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Anti-ifn-omega1 monoclonal antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
EP0490233A1 (de) * 1986-03-10 1992-06-17 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Monoclonale Antikörper gegen BgIII-Hybridinterferone, deren Verwendung und Verfahren zu ihrer Herstellung
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
ATE218362T1 (de) * 1997-12-19 2002-06-15 Applied Research Systems Ifnnar/ifn komplex
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2002343481A1 (en) * 2001-10-05 2003-04-22 Mount Sinais School Of Medecine Of New York University A hybrid fusion protein transcription regulator to induce interferon target gene expression
US20040243193A1 (en) 2003-05-30 2004-12-02 Ballis Joseph J. Electromagnetic interference alarm
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
WO2006086586A2 (en) 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2619725C (en) * 2005-08-18 2016-06-07 Ramot At Tel Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
MX2010012052A (es) * 2008-05-07 2010-12-14 Novo Nordisk As Anticuerpos humanizados contra interferon-alfa humano.
WO2010072740A2 (en) * 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
CN101691273B (zh) 2009-09-28 2012-07-04 广州普得环保设备有限公司 一种污水污泥浓缩脱水好氧风干一体化的方法
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CN103429616B (zh) 2010-09-27 2016-08-10 詹森生物科技公司 结合人胶原ii的抗体
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC

Also Published As

Publication number Publication date
AU2019200589A1 (en) 2019-02-21
EP2970461A4 (en) 2016-11-23
AU2014235003A1 (en) 2015-09-17
KR20150128849A (ko) 2015-11-18
CN105358575B (zh) 2020-09-22
WO2014151422A1 (en) 2014-09-25
HK1220474A1 (zh) 2017-05-05
US9902770B2 (en) 2018-02-27
JP2019081766A (ja) 2019-05-30
CA2906526C (en) 2022-12-06
EA201591813A1 (ru) 2016-03-31
EA038502B1 (ru) 2021-09-07
BR112015022988A2 (pt) 2017-11-14
CA2906526A1 (en) 2014-09-25
US20180002418A1 (en) 2018-01-04
ZA201507659B (en) 2017-11-29
JP6466904B2 (ja) 2019-02-06
IL241052A0 (en) 2015-11-30
US20190135912A1 (en) 2019-05-09
IL241052B (en) 2020-03-31
EP2970461A1 (en) 2016-01-20
US10155809B2 (en) 2018-12-18
CN105358575A (zh) 2016-02-24
US20140271648A1 (en) 2014-09-18
MX2015012728A (es) 2016-07-06
JP2016518330A (ja) 2016-06-23

Similar Documents

Publication Publication Date Title
MX366124B (es) Anticuerpos antagonistas del interferón alfa y omega.
MY182046A (en) Interferon alpha and omega antibody antagonists
IL282919A (en) Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
ZA201808352B (en) Pegylated porcine interferon and methods of use thereof
LT3849614T (lt) Interleukino-2 polipeptido konjugatai ir jų panaudojimas
EP3692636A4 (en) ELECTRONIC SWITCH AND DIMMER
EP3824750A4 (en) Electronic cigarette
EP3533138A4 (en) ELECTRONIC SWITCH AND DIMMER
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
UA113129C2 (xx) ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b
LT2996473T (lt) Kompozicijos ir būdai, skirti aktyvuoti nuo "interferono geno stimuliatoriaus" priklausomą signalinį kelią
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
EP3413172A4 (en) ELECTRONIC PIN
MY194084A (en) Interferon beta antibodies and uses thereof
EP3763731A4 (en) HMGN PARTIAL PEPTIDE AND CANCER THERAPY USING IT
EP3741227A4 (en) ELECTRONIC CIGARETTE
EP4139343A4 (en) Recombinant interferon
UA87208U (ru) Способ лечения ветряной оспы у детей
EP3819934A4 (en) ELECTRONIC MODULE
TH181995A (th) เฮเทอโรเอริลไดไฮโดรไพริมิดีนซึ่งถูกหลอมรวม-6 ที่ใหม่ สำหรับการรักษาและ การป้องกันโรคของการติดเชื้อไวรัสตับอักเสบ b
UA101995U (xx) Вертикальний віброконвеєр
UA86152U (ru) Способ лечения больных хроническим гепатитом с, которые имеют противопоказания к интерферонотерапии, и/или нон-респондеров

Legal Events

Date Code Title Description
FG Grant or registration